Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
Transmedics Group Inc (NASDAQ: TMDX) closed the day trading at $114.89 up 2.40% from the previous closing price of $112.2. In other words, the price has increased by $2.40 from its previous closing price. On the day, 0.61 million shares were traded. TMDX stock price reached its highest trading level at $114.89 during the session, while it also had its lowest trading level at $110.05.
Ratios:
For a better understanding of TMDX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.78 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 225.74. For the most recent quarter (mrq), Quick Ratio is recorded 9.17 and its Current Ratio is at 9.86. In the meantime, Its Debt-to-Equity ratio is 1.63 whereas as Long-Term Debt/Eq ratio is at 1.62.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Evercore ISI on September 16, 2025, initiated with a Outperform rating and assigned the stock a target price of $155.
On September 04, 2025, Stifel started tracking the stock assigning a Hold rating and target price of $115.
JP Morgan Downgraded its Overweight to Neutral on December 17, 2024, whereas the target price for the stock was revised from $116 to $75.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 06 ’25 when Hassanein Waleed H bought 8,400 shares for $118.68 per share. The transaction valued at 996,912 led to the insider holds 477,759 shares of the business.
Hassanein Waleed H bought 8,475 shares of TMDX for $985,209 on Aug 07 ’25. The President & CEO now owns 486,234 shares after completing the transaction at $116.25 per share. On Aug 04 ’25, another insider, Basile Edward M, who serves as the Director of the company, sold 4,143 shares for $125.51 each. As a result, the insider received 519,988 and left with 2,866 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 3916641024 and an Enterprise Value of 4034887936. As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 59.41, and their Forward P/E ratio for the next fiscal year is 40.86. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.07. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.37 while its Price-to-Book (P/B) ratio in mrq is 12.29. Its current Enterprise Value per Revenue stands at 7.594 whereas that against EBITDA is 40.227.
Stock Price History:
The Beta on a monthly basis for TMDX is 2.07, which has changed by -0.21974963 over the last 52 weeks, in comparison to a change of 0.17342639 over the same period for the S&P500. Over the past 52 weeks, TMDX has reached a high of $155.99, while it has fallen to a 52-week low of $55.00. The 50-Day Moving Average of the stock is -1.44%, while the 200-Day Moving Average is calculated to be 18.71%.
Shares Statistics:
Over the past 3-months, TMDX traded about 1.07M shares per day on average, while over the past 10 days, TMDX traded about 912430 shares per day. A total of 34.04M shares are outstanding, with a floating share count of 32.94M. Insiders hold about 3.36% of the company’s shares, while institutions hold 109.09% stake in the company. Shares short for TMDX as of 1757894400 were 8394299 with a Short Ratio of 7.85, compared to 1755216000 on 7841719. Therefore, it implies a Short% of Shares Outstanding of 8394299 and a Short% of Float of 42.310002000000004.
Earnings Estimates
The market rating for Transmedics Group Inc (TMDX) is a result of the insights provided by 7.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is $0.41, with high estimates of $0.47 and low estimates of $0.29.
Analysts are recommending an EPS of between $2.58 and $1.73 for the fiscal current year, implying an average EPS of $2.26. EPS for the following year is $2.83, with 8.0 analysts recommending between $3.55 and $2.2.
Revenue Estimates
9 analysts predict $145.33M in revenue for. The current quarter. It ranges from a high estimate of $148.6M to a low estimate of $140.5M. As of. The current estimate, Transmedics Group Inc’s year-ago sales were $108.76MFor the next quarter, 9 analysts are estimating revenue of $155.14M. There is a high estimate of $159.8M for the next quarter, whereas the lowest estimate is $148.61M.
A total of 11 analysts have provided revenue estimates for TMDX’s current fiscal year. The highest revenue estimate was $605M, while the lowest revenue estimate was $582.2M, resulting in an average revenue estimate of $599.14M. In the same quarter a year ago, actual revenue was $441.54MBased on 11 analysts’ estimates, the company’s revenue will be $723.65M in the next fiscal year. The high estimate is $764M and the low estimate is $687.4M.
